What's in SinoMab BioScience Ltd's pipeline?

SinoMab BioScience Ltd has 6 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with SinoMab BioScience Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sinomab-bioscience-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

SinoMab BioScience Ltd — Portfolio Competitive Intelligence Brief

SinoMab BioScience Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
SM03	SM03	phase 3	CD40 ligand inhibitor (monoclonal antibody)	CD40L (CD154)	Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for SinoMab BioScience Ltd:

Cite this brief

Drug Landscape (2026). SinoMab BioScience Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinomab-bioscience-ltd. Accessed 2026-05-13.